#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-18	Schizotypy-Related	_
1-2	19-32	Magnetization	_
1-3	33-35	of	_
1-4	36-42	Cortex	_
1-5	43-45	in	_
1-6	46-53	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
1-7	54-65	Adolescence	_
1-8	66-68	Is	_
1-9	69-78	Colocated	_
1-10	79-83	With	_
1-11	84-94	Expression	_
1-12	95-97	of	_
1-13	98-119	Schizophrenia-Related	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder
1-14	120-125	Genes	_
1-15	126-136	Background	_
1-16	137-144	Genetic	_
1-17	145-149	risk	_
1-18	150-152	is	_
1-19	153-160	thought	_
1-20	161-163	to	_
1-21	164-169	drive	_
1-22	170-178	clinical	_
1-23	179-188	variation	_
1-24	189-191	on	_
1-25	192-193	a	_
1-26	194-202	spectrum	_
1-27	203-205	of	_
1-28	206-224	schizophrenia-like	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-29	225-231	traits	_
1-30	232-233	,	_
1-31	234-237	but	_
1-32	238-241	the	_
1-33	242-252	underlying	_
1-34	253-260	changes	_
1-35	261-263	in	_
1-36	264-269	brain	_
1-37	270-279	structure	_
1-38	280-284	that	_
1-39	285-300	mechanistically	_
1-40	301-305	link	_
1-41	306-313	genomic	_
1-42	314-323	variation	_
1-43	324-326	to	_
1-44	327-338	schizotypal	_
1-45	339-349	experience	_
1-46	350-353	and	_
1-47	354-362	behavior	_
1-48	363-366	are	_
1-49	367-374	unclear	_
1-50	375-376	.	_

2-1	377-384	Methods	_
2-2	385-387	We	_
2-3	388-396	assessed	_
2-4	397-407	schizotypy	_
2-5	408-413	using	_
2-6	414-415	a	_
2-7	416-429	self-reported	_
2-8	430-443	questionnaire	_
2-9	444-447	and	_
2-10	448-456	measured	_
2-11	457-470	magnetization	_
2-12	471-479	transfer	_
2-13	480-482	as	_
2-14	483-484	a	_
2-15	485-493	putative	_
2-16	494-509	microstructural	_
2-17	510-518	magnetic	_
2-18	519-528	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
2-19	529-536	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
2-20	537-543	marker	_
2-21	544-546	of	_
2-22	547-560	intracortical	_
2-23	561-572	myelination	_
2-24	573-575	in	_
2-25	576-578	68	_
2-26	579-584	brain	_
2-27	585-592	regions	_
2-28	593-595	in	_
2-29	596-599	248	_
2-30	600-607	healthy	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
2-31	608-613	young	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
2-32	614-620	people	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
2-33	621-622	(	_
2-34	623-628	14–25	_
2-35	629-634	years	_
2-36	635-637	of	_
2-37	638-641	age	_
2-38	642-643	)	_
2-39	644-645	.	_

3-1	646-648	We	_
3-2	649-653	used	_
3-3	654-663	normative	_
3-4	664-669	adult	_
3-5	670-675	brain	_
3-6	676-680	gene	_
3-7	681-691	expression	_
3-8	692-696	data	_
3-9	697-700	and	_
3-10	701-708	partial	_
3-11	709-714	least	_
3-12	715-722	squares	_
3-13	723-731	analysis	_
3-14	732-734	to	_
3-15	735-739	find	_
3-16	740-743	the	_
3-17	744-752	weighted	_
3-18	753-757	gene	_
3-19	758-768	expression	_
3-20	769-776	pattern	_
3-21	777-781	that	_
3-22	782-785	was	_
3-23	786-790	most	_
3-24	791-800	colocated	_
3-25	801-805	with	_
3-26	806-809	the	_
3-27	810-818	cortical	_
3-28	819-822	map	_
3-29	823-825	of	_
3-30	826-844	schizotypy-related	_
3-31	845-858	magnetization	_
3-32	859-860	.	_

4-1	861-868	Results	_
4-2	869-882	Magnetization	_
4-3	883-886	was	_
4-4	887-900	significantly	_
4-5	901-911	correlated	_
4-6	912-916	with	_
4-7	917-927	schizotypy	_
4-8	928-930	in	_
4-9	931-934	the	_
4-10	935-944	bilateral	_
4-11	945-954	posterior	_
4-12	955-964	cingulate	_
4-13	965-971	cortex	_
4-14	972-975	and	_
4-15	976-985	precuneus	_
4-16	986-987	(	_
4-17	988-991	and	_
4-18	992-995	for	_
4-19	996-1008	disorganized	_
4-20	1009-1019	schizotypy	_
4-21	1020-1021	,	_
4-22	1022-1026	also	_
4-23	1027-1029	in	_
4-24	1030-1036	medial	_
4-25	1037-1047	prefrontal	_
4-26	1048-1054	cortex	_
4-27	1055-1056	;	_
4-28	1057-1060	all	_
4-29	1061-1066	false	_
4-30	1067-1076	discovery	_
4-31	1077-1091	rate–corrected	_
4-32	1092-1094	ps	_
4-33	1095-1096	<	_
4-34	1097-1100	.05	_
4-35	1101-1102	)	_
4-36	1103-1104	,	_
4-37	1105-1110	which	_
4-38	1111-1114	are	_
4-39	1115-1122	regions	_
4-40	1123-1125	of	_
4-41	1126-1129	the	_
4-42	1130-1137	default	_
4-43	1138-1142	mode	_
4-44	1143-1150	network	_
4-45	1151-1162	specialized	_
4-46	1163-1166	for	_
4-47	1167-1173	social	_
4-48	1174-1177	and	_
4-49	1178-1184	memory	_
4-50	1185-1194	functions	_
4-51	1195-1196	.	_

5-1	1197-1200	The	_
5-2	1201-1206	genes	_
5-3	1207-1211	most	_
5-4	1212-1222	positively	_
5-5	1223-1231	weighted	_
5-6	1232-1234	on	_
5-7	1235-1238	the	_
5-8	1239-1251	whole-genome	_
5-9	1252-1262	expression	_
5-10	1263-1266	map	_
5-11	1267-1276	colocated	_
5-12	1277-1281	with	_
5-13	1282-1300	schizotypy-related	_
5-14	1301-1314	magnetization	_
5-15	1315-1319	were	_
5-16	1320-1328	enriched	_
5-17	1329-1332	for	_
5-18	1333-1338	genes	_
5-19	1339-1343	that	_
5-20	1344-1348	were	_
5-21	1349-1362	significantly	_
5-22	1363-1376	downregulated	_
5-23	1377-1379	in	_
5-24	1380-1383	two	_
5-25	1384-1389	prior	_
5-26	1390-1402	case-control	_
5-27	1403-1415	histological	_
5-28	1416-1423	studies	_
5-29	1424-1426	of	_
5-30	1427-1432	brain	_
5-31	1433-1437	gene	_
5-32	1438-1448	expression	_
5-33	1449-1451	in	_
5-34	1452-1465	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-35	1466-1467	.	_

6-1	1468-1478	Conversely	_
6-2	1479-1480	,	_
6-3	1481-1484	the	_
6-4	1485-1489	most	_
6-5	1490-1500	negatively	_
6-6	1501-1509	weighted	_
6-7	1510-1515	genes	_
6-8	1516-1520	were	_
6-9	1521-1529	enriched	_
6-10	1530-1533	for	_
6-11	1534-1539	genes	_
6-12	1540-1544	that	_
6-13	1545-1549	were	_
6-14	1550-1567	transcriptionally	_
6-15	1568-1579	upregulated	_
6-16	1580-1582	in	_
6-17	1583-1596	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-18	1597-1598	.	_

7-1	1599-1609	Positively	_
7-2	1610-1618	weighted	_
7-3	1619-1620	(	_
7-4	1621-1634	downregulated	_
7-5	1635-1636	)	_
7-6	1637-1642	genes	_
7-7	1643-1647	were	_
7-8	1648-1656	enriched	_
7-9	1657-1660	for	_
7-10	1661-1669	neuronal	_
7-11	1670-1671	,	_
7-12	1672-1684	specifically	_
7-13	1685-1698	interneuronal	_
7-14	1699-1700	,	_
7-15	1701-1713	affiliations	_
7-16	1714-1717	and	_
7-17	1718-1723	coded	_
7-18	1724-1725	a	_
7-19	1726-1733	network	_
7-20	1734-1736	of	_
7-21	1737-1745	proteins	_
7-22	1746-1756	comprising	_
7-23	1757-1758	a	_
7-24	1759-1762	few	_
7-25	1763-1769	highly	_
7-26	1770-1781	interactive	_
7-27	1782-1783	“	_
7-28	1784-1788	hubs	_
7-29	1789-1790	”	_
7-30	1791-1795	such	_
7-31	1796-1798	as	_
7-32	1799-1810	parvalbumin	_
7-33	1811-1814	and	_
7-34	1815-1825	calmodulin	_
7-35	1826-1827	.	_

8-1	1828-1839	Conclusions	_
8-2	1840-1855	Microstructural	_
8-3	1856-1864	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
8-4	1865-1874	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
8-5	1875-1882	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
8-6	1883-1887	maps	_
8-7	1888-1890	of	_
8-8	1891-1904	intracortical	_
8-9	1905-1918	magnetization	_
8-10	1919-1922	can	_
8-11	1923-1925	be	_
8-12	1926-1932	linked	_
8-13	1933-1935	to	_
8-14	1936-1940	both	_
8-15	1941-1944	the	_
8-16	1945-1955	behavioral	_
8-17	1956-1962	traits	_
8-18	1963-1965	of	_
8-19	1966-1976	schizotypy	_
8-20	1977-1980	and	_
8-21	1981-1986	prior	_
8-22	1987-1999	histological	_
8-23	2000-2004	data	_
8-24	2005-2007	on	_
8-25	2008-2020	dysregulated	_
8-26	2021-2025	gene	_
8-27	2026-2036	expression	_
8-28	2037-2039	in	_
8-29	2040-2053	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-30	2054-2055	.	_

9-1	2056-2063	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-2	2064-2067	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-3	2068-2077	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-4	2078-2090	Participants	_
9-5	2091-2092	A	_
9-6	2093-2098	total	_
9-7	2099-2101	of	_
9-8	2102-2106	2135	_
9-9	2107-2114	healthy	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
9-10	2115-2120	young	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
9-11	2121-2127	people	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
9-12	2128-2129	,	_
9-13	2130-2132	14	_
9-14	2133-2135	to	_
9-15	2136-2138	25	_
9-16	2139-2144	years	_
9-17	2145-2147	of	_
9-18	2148-2151	age	_
9-19	2152-2153	,	_
9-20	2154-2158	were	_
9-21	2159-2168	recruited	_
9-22	2169-2173	from	_
9-23	2174-2181	schools	_
9-24	2182-2183	,	_
9-25	2184-2192	colleges	_
9-26	2193-2194	,	_
9-27	2195-2203	National	_
9-28	2204-2210	Health	_
9-29	2211-2218	Service	_
9-30	2219-2226	primary	_
9-31	2227-2231	care	_
9-32	2232-2240	services	_
9-33	2241-2242	,	_
9-34	2243-2246	and	_
9-35	2247-2253	direct	_
9-36	2254-2267	advertisement	_
9-37	2268-2270	in	_
9-38	2271-2276	north	_
9-39	2277-2283	London	_
9-40	2284-2287	and	_
9-41	2288-2302	Cambridgeshire	_
9-42	2303-2304	,	_
9-43	2305-2311	United	_
9-44	2312-2319	Kingdom	_
9-45	2320-2321	.	_

10-1	2322-2326	This	_
10-2	2327-2334	primary	_
10-3	2335-2341	cohort	_
10-4	2342-2345	was	_
10-5	2346-2356	stratified	_
10-6	2357-2361	into	_
10-7	2362-2363	5	_
10-8	2364-2374	contiguous	_
10-9	2375-2386	age-related	_
10-10	2387-2393	strata	_
10-11	2394-2395	,	_
10-12	2396-2404	balanced	_
10-13	2405-2408	for	_
10-14	2409-2415	gender	_
10-15	2416-2419	and	_
10-16	2420-2429	ethnicity	_
10-17	2430-2431	.	_

11-1	2432-2433	A	_
11-2	2434-2443	secondary	_
11-3	2444-2450	cohort	_
11-4	2451-2453	of	_
11-5	2454-2457	297	_
11-6	2458-2469	individuals	_
11-7	2470-2473	was	_
11-8	2474-2483	recruited	_
11-9	2484-2486	by	_
11-10	2487-2495	randomly	_
11-11	2496-2507	subsampling	_
11-12	2508-2511	the	_
11-13	2512-2519	primary	_
11-14	2520-2526	cohort	_
11-15	2527-2529	so	_
11-16	2530-2534	that	_
11-17	2535-2538	∼60	_
11-18	2539-2551	participants	_
11-19	2552-2556	were	_
11-20	2557-2565	assigned	_
11-21	2566-2568	to	_
11-22	2569-2573	each	_
11-23	2574-2576	of	_
11-24	2577-2580	the	_
11-25	2581-2585	same	_
11-26	2586-2597	age-related	_
11-27	2598-2604	strata	_
11-28	2605-2606	,	_
11-29	2607-2615	balanced	_
11-30	2616-2619	for	_
11-31	2620-2626	gender	_
11-32	2627-2630	and	_
11-33	2631-2640	ethnicity	_
11-34	2641-2642	,	_
11-35	2643-2645	as	_
11-36	2646-2648	in	_
11-37	2649-2652	the	_
11-38	2653-2660	primary	_
11-39	2661-2667	cohort	_
11-40	2668-2669	.	_

12-1	2670-2682	Participants	_
12-2	2683-2687	were	_
12-3	2688-2696	excluded	_
12-4	2697-2699	if	_
12-5	2700-2704	they	_
12-6	2705-2708	had	_
12-7	2709-2710	a	_
12-8	2711-2718	current	_
12-9	2719-2721	or	_
12-10	2722-2726	past	_
12-11	2727-2734	history	_
12-12	2735-2737	of	_
12-13	2738-2746	clinical	_
12-14	2747-2756	treatment	_
12-15	2757-2760	for	_
12-16	2761-2762	a	_
12-17	2763-2774	psychiatric	_
12-18	2775-2783	disorder	_
12-19	2784-2785	,	_
12-20	2786-2790	drug	_
12-21	2791-2793	or	_
12-22	2794-2801	alcohol	_
12-23	2802-2812	dependence	_
12-24	2813-2814	,	_
12-25	2815-2827	neurological	_
12-26	2828-2836	disorder	_
12-27	2837-2846	including	_
12-28	2847-2855	epilepsy	_
12-29	2856-2857	,	_
12-30	2858-2862	head	_
12-31	2863-2869	injury	_
12-32	2870-2877	causing	_
12-33	2878-2882	loss	_
12-34	2883-2885	of	_
12-35	2886-2899	consciousness	_
12-36	2900-2901	,	_
12-37	2902-2904	or	_
12-38	2905-2913	learning	_
12-39	2914-2924	disability	_
12-40	2925-2926	(	_
12-41	2927-2930	see	_
12-42	2931-2941	Supplement	_
12-43	2942-2945	for	_
12-44	2946-2953	details	_
12-45	2954-2955	)	_
12-46	2956-2957	.	_

13-1	2958-2965	Written	_
13-2	2966-2974	informed	_
13-3	2975-2982	consent	_
13-4	2983-2986	was	_
13-5	2987-2995	provided	_
13-6	2996-2998	by	_
13-7	2999-3002	all	_
13-8	3003-3015	participants	_
13-9	3016-3018	as	_
13-10	3019-3023	well	_
13-11	3024-3026	as	_
13-12	3027-3034	written	_
13-13	3035-3043	parental	_
13-14	3044-3050	assent	_
13-15	3051-3054	for	_
13-16	3055-3067	participants	_
13-17	3068-3072	less	_
13-18	3073-3077	than	_
13-19	3078-3080	16	_
13-20	3081-3086	years	_
13-21	3087-3089	of	_
13-22	3090-3093	age	_
13-23	3094-3095	.	_

14-1	3096-3099	The	_
14-2	3100-3105	study	_
14-3	3106-3109	was	_
14-4	3110-3118	approved	_
14-5	3119-3121	by	_
14-6	3122-3125	the	_
14-7	3126-3134	National	_
14-8	3135-3143	Research	_
14-9	3144-3150	Ethics	_
14-10	3151-3158	Service	_
14-11	3159-3162	and	_
14-12	3163-3172	conducted	_
14-13	3173-3175	in	_
14-14	3176-3186	accordance	_
14-15	3187-3191	with	_
14-16	3192-3200	National	_
14-17	3201-3207	Health	_
14-18	3208-3215	Service	_
14-19	3216-3224	research	_
14-20	3225-3235	governance	_
14-21	3236-3245	standards	_
14-22	3246-3247	.	_

15-1	3248-3258	Schizotypy	_
15-2	3259-3269	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#SchizotypalPersonalityQuestionnaire
15-3	3270-3273	The	http://maven.renci.org/NeuroBridge/neurobridge#SchizotypalPersonalityQuestionnaire
15-4	3274-3277	SPQ	http://maven.renci.org/NeuroBridge/neurobridge#SchizotypalPersonalityQuestionnaire
15-5	3278-3280	is	_
15-6	3281-3282	a	_
15-7	3283-3294	self-report	_
15-8	3295-3300	scale	_
15-9	3301-3302	,	_
15-10	3303-3313	comprising	_
15-11	3314-3316	74	_
15-12	3317-3328	dichotomous	_
15-13	3329-3334	items	_
15-14	3335-3339	that	_
15-15	3340-3343	are	_
15-16	3344-3351	grouped	_
15-17	3352-3354	on	_
15-18	3355-3356	9	_
15-19	3357-3366	subscales	_
15-20	3367-3368	,	_
15-21	3369-3378	measuring	_
15-22	3379-3382	the	_
15-23	3383-3390	complex	_
15-24	3391-3396	trait	_
15-25	3397-3399	of	_
15-26	3400-3410	schizotypy	_
15-27	3411-3412	.	_

16-1	3413-3425	Participants	_
16-2	3426-3435	completed	_
16-3	3436-3439	the	_
16-4	3440-3443	SPQ	_
16-5	3444-3446	on	_
16-6	3447-3448	2	_
16-7	3449-3460	assessments	_
16-8	3461-3462	,	_
16-9	3463-3472	separated	_
16-10	3473-3475	by	_
16-11	3476-3477	6	_
16-12	3478-3480	to	_
16-13	3481-3483	18	_
16-14	3484-3490	months	_
16-15	3491-3492	,	_
16-16	3493-3495	so	_
16-17	3496-3500	that	_
16-18	3501-3510	traitlike	_
16-19	3511-3517	scores	_
16-20	3518-3520	on	_
16-21	3521-3526	total	_
16-22	3527-3530	and	_
16-23	3531-3539	subscale	_
16-24	3540-3543	SPQ	_
16-25	3544-3551	metrics	_
16-26	3552-3557	could	_
16-27	3558-3560	be	_
16-28	3561-3570	estimated	_
16-29	3571-3573	by	_
16-30	3574-3577	the	_
16-31	3578-3584	number	_
16-32	3585-3587	of	_
16-33	3588-3601	questionnaire	_
16-34	3602-3607	items	_
16-35	3608-3618	positively	_
16-36	3619-3627	endorsed	_
16-37	3628-3630	by	_
16-38	3631-3635	each	_
16-39	3636-3647	participant	_
16-40	3648-3650	on	_
16-41	3651-3658	average	_
16-42	3659-3663	over	_
16-43	3664-3668	time	_
16-44	3669-3670	.	_

17-1	3671-3674	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
17-2	3675-3679	Data	_
17-3	3680-3691	Acquisition	_
17-4	3692-3702	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
17-5	3703-3706	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
17-6	3707-3712	scans	_
17-7	3713-3717	were	_
17-8	3718-3726	acquired	_
17-9	3727-3729	on	_
17-10	3730-3731	1	_
17-11	3732-3734	of	_
17-12	3735-3736	3	_
17-13	3737-3746	identical	_
17-14	3747-3749	3T	http://maven.renci.org/NeuroBridge/neurobridge#Thing
17-15	3750-3753	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
17-16	3754-3761	systems	_
17-17	3762-3764	in	_
17-18	3765-3771	London	_
17-19	3772-3774	or	_
17-20	3775-3784	Cambridge	_
17-21	3785-3786	,	_
17-22	3787-3793	United	_
17-23	3794-3801	Kingdom	_
17-24	3802-3803	(	_
17-25	3804-3812	Magnetom	_
17-26	3813-3816	TIM	_
17-27	3817-3821	Trio	_
17-28	3822-3823	[	_
17-29	3824-3831	Siemens	_
17-30	3832-3842	Healthcare	_
17-31	3843-3844	,	_
17-32	3845-3853	Erlangen	_
17-33	3854-3855	,	_
17-34	3856-3863	Germany	_
17-35	3864-3865	]	_
17-36	3866-3867	,	_
17-37	3868-3876	software	_
17-38	3877-3884	version	_
17-39	3885-3889	VB17	_
17-40	3890-3891	)	_
17-41	3892-3893	.	_

18-1	3894-3897	The	_
18-2	3898-3913	multiparametric	_
18-3	3914-3921	mapping	_
18-4	3922-3930	protocol	_
18-5	3931-3938	yielded	_
18-6	3939-3940	3	_
18-7	3941-3950	multiecho	_
18-8	3951-3955	fast	_
18-9	3956-3965	low-angle	_
18-10	3966-3970	shot	_
18-11	3971-3976	scans	_
18-12	3977-3981	with	_
18-13	3982-3990	variable	_
18-14	3991-4001	excitation	_
18-15	4002-4006	flip	_
18-16	4007-4013	angles	_
18-17	4014-4015	.	_

19-1	4016-4018	By	_
19-2	4019-4030	appropriate	_
19-3	4031-4037	choice	_
19-4	4038-4040	of	_
19-5	4041-4051	repetition	_
19-6	4052-4056	time	_
19-7	4057-4060	and	_
19-8	4061-4065	flip	_
19-9	4066-4071	angle	_
19-10	4072-4073	α	_
19-11	4074-4075	,	_
19-12	4076-4088	acquisitions	_
19-13	4089-4093	were	_
19-14	4094-4107	predominantly	_
19-15	4108-4116	weighted	_
19-16	4117-4119	by	_
19-17	4120-4122	T1	_
19-18	4123-4124	(	_
19-19	4125-4135	repetition	_
19-20	4136-4140	time	_
19-21	4141-4142	=	_
19-22	4143-4147	18.7	_
19-23	4148-4150	ms	_
19-24	4151-4152	,	_
19-25	4153-4154	α	_
19-26	4155-4156	=	_
19-27	4157-4160	20°	_
19-28	4161-4162	)	_
19-29	4163-4164	,	_
19-30	4165-4171	proton	_
19-31	4172-4179	density	_
19-32	4180-4181	,	_
19-33	4182-4184	or	_
19-34	4185-4187	MT	_
19-35	4188-4189	(	_
19-36	4190-4200	repetition	_
19-37	4201-4205	time	_
19-38	4206-4207	=	_
19-39	4208-4212	23.7	_
19-40	4213-4215	ms	_
19-41	4216-4217	,	_
19-42	4218-4219	α	_
19-43	4220-4221	=	_
19-44	4222-4224	6°	_
19-45	4225-4226	)	_
19-46	4227-4228	.	_

20-1	4229-4234	Other	_
20-2	4235-4246	acquisition	_
20-3	4247-4257	parameters	_
20-4	4258-4262	were	_
20-5	4263-4268	1-mm3	_
20-6	4269-4274	voxel	_
20-7	4275-4285	resolution	_
20-8	4286-4287	,	_
20-9	4288-4291	176	_
20-10	4292-4300	sagittal	_
20-11	4301-4307	slices	_
20-12	4308-4309	,	_
20-13	4310-4313	and	_
20-14	4314-4315	a	_
20-15	4316-4321	field	_
20-16	4322-4324	of	_
20-17	4325-4329	view	_
20-18	4330-4332	of	_
20-19	4333-4336	256	_
20-20	4337-4338	×	_
20-21	4339-4342	240	_
20-22	4343-4345	mm	_
20-23	4346-4347	.	_

21-1	4348-4349	A	_
21-2	4350-4355	pilot	_
21-3	4356-4361	study	_
21-4	4362-4374	demonstrated	_
21-5	4375-4387	satisfactory	_
21-6	4388-4394	levels	_
21-7	4395-4397	of	_
21-8	4398-4410	between-site	_
21-9	4411-4422	reliability	_
21-10	4423-4425	in	_
21-11	4426-4441	multiparametric	_
21-12	4442-4449	mapping	_
21-13	4450-4454	data	_
21-14	4455-4466	acquisition	_
21-15	4467-4468	.	_

22-1	4469-4471	MT	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
22-2	4472-4478	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
22-3	4479-4482	and	_
22-4	4483-4485	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
22-5	4486-4492	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
22-6	4493-4497	from	_
22-7	4498-4502	this	_
22-8	4503-4509	sample	_
22-9	4510-4514	have	_
22-10	4515-4519	been	_
22-11	4520-4530	previously	_
22-12	4531-4539	reported	_
22-13	4540-4541	.	_

23-1	4542-4545	MRI	_
23-2	4546-4560	Reconstruction	_
23-3	4561-4562	,	_
23-4	4563-4571	Cortical	_
23-5	4572-4584	Parcellation	_
23-6	4585-4586	,	_
23-7	4587-4590	and	_
23-8	4591-4601	Estimation	_
23-9	4602-4604	of	_
23-10	4605-4608	SRM	_
23-11	4609-4611	We	_
23-12	4612-4616	used	_
23-13	4617-4618	a	_
23-14	4619-4627	standard	_
23-15	4628-4637	automated	_
23-16	4638-4648	processing	_
23-17	4649-4657	pipeline	_
23-18	4658-4661	for	_
23-19	4662-4667	skull	_
23-20	4668-4677	stripping	_
23-21	4678-4679	,	_
23-22	4680-4686	tissue	_
23-23	4687-4700	classiﬁcation	_
23-24	4701-4702	,	_
23-25	4703-4710	surface	_
23-26	4711-4721	extraction	_
23-27	4722-4723	,	_
23-28	4724-4727	and	_
23-29	4728-4736	cortical	_
23-30	4737-4749	parcellation	_
23-31	4750-4751	(	_
23-32	4752-4762	FreeSurfer	_
23-33	4763-4764	[	_
23-34	4765-4769	http	_
23-35	4770-4771	:	_
23-36	4772-4800	//surfer.nmr.mgh.harvard.edu	_
23-37	4801-4802	]	_
23-38	4803-4804	)	_
23-39	4805-4812	applied	_
23-40	4813-4815	to	_
23-41	4816-4828	longitudinal	_
23-42	4829-4839	relaxation	_
23-43	4840-4844	rate	_
23-44	4845-4846	(	_
23-45	4847-4849	R1	_
23-46	4850-4851	)	_
23-47	4852-4856	maps	_
23-48	4857-4858	(	_
23-49	4859-4861	R1	_
23-50	4862-4863	=	_
23-51	4864-4868	1/T1	_
23-52	4869-4870	)	_
23-53	4871-4872	.	_

24-1	4873-4879	Expert	_
24-2	4880-4886	visual	_
24-3	4887-4894	quality	_
24-4	4895-4902	control	_
24-5	4903-4910	ensured	_
24-6	4911-4919	accurate	_
24-7	4920-4932	segmentation	_
24-8	4933-4935	of	_
24-9	4936-4940	pial	_
24-10	4941-4944	and	_
24-11	4945-4955	gray/white	_
24-12	4956-4962	matter	_
24-13	4963-4973	boundaries	_
24-14	4974-4975	.	_

25-1	4976-4984	Regional	_
25-2	4985-4987	MT	_
25-3	4988-4994	values	_
25-4	4995-4999	were	_
25-5	5000-5009	estimated	_
25-6	5010-5012	at	_
25-7	5013-5017	each	_
25-8	5018-5020	of	_
25-9	5021-5023	68	_
25-10	5024-5032	cortical	_
25-11	5033-5040	regions	_
25-12	5041-5044	for	_
25-13	5045-5049	each	_
25-14	5050-5057	subject	_
25-15	5058-5059	,	_
25-16	5060-5069	resulting	_
25-17	5070-5072	in	_
25-18	5073-5074	a	_
25-19	5075-5078	248	_
25-20	5079-5080	×	_
25-21	5081-5083	68	_
25-22	5084-5092	regional	_
25-23	5093-5095	MT	_
25-24	5096-5100	data	_
25-25	5101-5107	matrix	_
25-26	5108-5109	.	_

26-1	5110-5113	The	_
26-2	5114-5119	Euler	_
26-3	5120-5126	number	_
26-4	5127-5130	for	_
26-5	5131-5134	the	_
26-6	5135-5137	R1	_
26-7	5138-5144	images	_
26-8	5145-5148	was	_
26-9	5149-5159	calculated	_
26-10	5160-5162	as	_
26-11	5163-5164	a	_
26-12	5165-5170	proxy	_
26-13	5171-5178	measure	_
26-14	5179-5181	of	_
26-15	5182-5187	image	_
26-16	5188-5195	quality	_
26-17	5196-5198	in	_
26-18	5199-5202	the	_
26-19	5203-5217	simultaneously	_
26-20	5218-5226	acquired	_
26-21	5227-5229	MT	_
26-22	5230-5236	images	_
26-23	5237-5238	.	_

27-1	5239-5240	A	_
27-2	5241-5247	simple	_
27-3	5248-5254	linear	_
27-4	5255-5260	model	_
27-5	5261-5263	of	_
27-6	5264-5275	age-related	_
27-7	5276-5282	change	_
27-8	5283-5285	in	_
27-9	5286-5288	MT	_
27-10	5289-5292	was	_
27-11	5293-5297	used	_
27-12	5298-5300	to	_
27-13	5301-5309	estimate	_
27-14	5310-5313	two	_
27-15	5314-5317	key	_
27-16	5318-5328	parameters	_
27-17	5329-5332	for	_
27-18	5333-5337	each	_
27-19	5338-5344	region	_
27-20	5345-5346	:	_
27-21	5347-5355	baseline	_
27-22	5356-5358	MT	_
27-23	5359-5361	at	_
27-24	5362-5364	14	_
27-25	5365-5370	years	_
27-26	5371-5373	of	_
27-27	5374-5377	age	_
27-28	5378-5381	and	_
27-29	5382-5393	age-related	_
27-30	5394-5398	rate	_
27-31	5399-5401	of	_
27-32	5402-5408	change	_
27-33	5409-5411	in	_
27-34	5412-5415	the	_
27-35	5416-5422	period	_
27-36	5423-5427	from	_
27-37	5428-5430	14	_
27-38	5431-5433	to	_
27-39	5434-5436	24	_
27-40	5437-5442	years	_
27-41	5443-5445	of	_
27-42	5446-5449	age	_
27-43	5450-5451	.	_

28-1	5452-5455	For	_
28-2	5456-5459	the	_
28-3	5460-5469	principal	_
28-4	5470-5478	analyses	_
28-5	5479-5480	,	_
28-6	5481-5488	effects	_
28-7	5489-5491	of	_
28-8	5492-5495	age	_
28-9	5496-5498	on	_
28-10	5499-5501	MT	_
28-11	5502-5506	were	_
28-12	5507-5517	controlled	_
28-13	5518-5520	by	_
28-14	5521-5531	regression	_
28-15	5532-5538	before	_
28-16	5539-5549	estimating	_
28-17	5550-5553	the	_
28-18	5554-5565	correlation	_
28-19	5566-5568	of	_
28-20	5569-5572	the	_
28-21	5573-5586	age-corrected	_
28-22	5587-5589	MT	_
28-23	5590-5599	residuals	_
28-24	5600-5604	with	_
28-25	5605-5608	SPQ	_
28-26	5609-5614	total	_
28-27	5615-5620	score	_
28-28	5621-5622	.	_

29-1	5623-5626	The	_
29-2	5627-5645	Kolmogorov-Smirnov	_
29-3	5646-5655	normality	_
29-4	5656-5660	test	_
29-5	5661-5664	was	_
29-6	5665-5669	used	_
29-7	5670-5672	to	_
29-8	5673-5682	determine	_
29-9	5683-5686	the	_
29-10	5687-5698	appropriate	_
29-11	5699-5710	correlation	_
29-12	5711-5720	estimator	_
29-13	5721-5722	(	_
29-14	5723-5730	Pearson	_
29-15	5731-5732	’	_
29-16	5733-5734	s	_
29-17	5735-5737	or	_
29-18	5738-5746	Spearman	_
29-19	5747-5748	’	_
29-20	5749-5750	s	_
29-21	5751-5752	)	_
29-22	5753-5754	.	_

30-1	5755-5765	Estimation	_
30-2	5766-5768	of	_
30-3	5769-5777	Regional	_
30-4	5778-5782	Gene	_
30-5	5783-5793	Expression	_
30-6	5794-5796	We	_
30-7	5797-5801	used	_
30-8	5802-5805	the	_
30-9	5806-5811	Allen	http://maven.renci.org/NeuroBridge/neurobridge#Hallucination
30-10	5812-5817	Human	http://maven.renci.org/NeuroBridge/neurobridge#Hallucination
30-11	5818-5823	Brain	http://maven.renci.org/NeuroBridge/neurobridge#Hallucination
30-12	5824-5829	Atlas	http://maven.renci.org/NeuroBridge/neurobridge#Hallucination
30-13	5830-5831	(	http://maven.renci.org/NeuroBridge/neurobridge#Hallucination
30-14	5832-5836	AHBA	http://maven.renci.org/NeuroBridge/neurobridge#Hallucination
30-15	5837-5838	)	http://maven.renci.org/NeuroBridge/neurobridge#Hallucination
30-16	5839-5840	,	_
30-17	5841-5842	a	_
30-18	5843-5855	whole-genome	_
30-19	5856-5866	expression	_
30-20	5867-5872	atlas	_
30-21	5873-5875	of	_
30-22	5876-5879	the	_
30-23	5880-5885	adult	_
30-24	5886-5891	human	_
30-25	5892-5897	brain	_
30-26	5898-5905	created	_
30-27	5906-5908	by	_
30-28	5909-5912	the	_
30-29	5913-5918	Allen	_
30-30	5919-5928	Institute	_
30-31	5929-5932	for	_
30-32	5933-5938	Brain	_
30-33	5939-5947	Sciences	_
30-34	5948-5953	using	_
30-35	5954-5955	6	_
30-36	5956-5962	donors	_
30-37	5963-5965	24	_
30-38	5966-5968	to	_
30-39	5969-5971	57	_
30-40	5972-5977	years	_
30-41	5978-5980	of	_
30-42	5981-5984	age	_
30-43	5985-5986	(	_
30-44	5987-5991	http	_
30-45	5992-5993	:	_
30-46	5994-6015	//human.brain-map.org	_
30-47	6016-6017	)	_
30-48	6018-6019	.	_

31-1	6020-6033	Probe-to-gene	_
31-2	6034-6037	and	_
31-3	6038-6054	sample-to-region	_
31-4	6055-6062	mapping	_
31-5	6063-6073	strategies	_
31-6	6074-6077	can	_
31-7	6078-6082	have	_
31-8	6083-6084	a	_
31-9	6085-6090	major	_
31-10	6091-6097	impact	_
31-11	6098-6100	on	_
31-12	6101-6109	regional	_
31-13	6110-6114	gene	_
31-14	6115-6125	expression	_
31-15	6126-6136	estimation	_
31-16	6137-6138	.	_

32-1	6139-6143	Here	_
32-2	6144-6145	,	_
32-3	6146-6148	we	_
32-4	6149-6153	used	_
32-5	6154-6157	the	_
32-6	6158-6164	genome	_
32-7	6165-6173	assembly	_
32-8	6174-6178	hg19	_
32-9	6179-6180	(	_
32-10	6181-6185	http	_
32-11	6186-6187	:	_
32-12	6188-6227	//sourceforge.net/projects/reannotator/	_
32-13	6228-6229	)	_
32-14	6230-6232	to	_
32-15	6233-6243	reannotate	_
32-16	6244-6247	the	_
32-17	6248-6253	probe	_
32-18	6254-6263	sequences	_
32-19	6264-6268	into	_
32-20	6269-6274	genes	_
32-21	6275-6276	.	_

33-1	6277-6281	When	_
33-2	6282-6287	genes	_
33-3	6288-6292	were	_
33-4	6293-6299	mapped	_
33-5	6300-6302	by	_
33-6	6303-6311	multiple	_
33-7	6312-6325	complementary	_
33-8	6326-6329	RNA	_
33-9	6330-6343	hybridization	_
33-10	6344-6350	probes	_
33-11	6351-6352	,	_
33-12	6353-6356	the	_
33-13	6357-6362	probe	_
33-14	6363-6370	showing	_
33-15	6371-6374	the	_
33-16	6375-6382	highest	_
33-17	6383-6390	average	_
33-18	6391-6401	expression	_
33-19	6402-6408	across	_
33-20	6409-6416	samples	_
33-21	6417-6420	was	_
33-22	6421-6429	selected	_
33-23	6430-6431	.	_

34-1	6432-6435	MRI	_
34-2	6436-6442	images	_
34-3	6443-6445	of	_
34-4	6446-6449	the	_
34-5	6450-6454	AHBA	_
34-6	6455-6461	donors	_
34-7	6462-6466	were	_
34-8	6467-6478	parcellated	_
34-9	6479-6484	using	_
34-10	6485-6488	the	_
34-11	6489-6505	Desikan-Killiany	_
34-12	6506-6511	atlas	_
34-13	6512-6513	,	_
34-14	6514-6517	and	_
34-15	6518-6522	each	_
34-16	6523-6531	cortical	_
34-17	6532-6538	tissue	_
34-18	6539-6545	sample	_
34-19	6546-6549	was	_
34-20	6550-6558	assigned	_
34-21	6559-6561	to	_
34-22	6562-6564	an	_
34-23	6565-6575	anatomical	_
34-24	6576-6585	structure	_
34-25	6586-6587	.	_

35-1	6588-6596	Regional	_
35-2	6597-6607	expression	_
35-3	6608-6614	levels	_
35-4	6615-6619	were	_
35-5	6620-6628	compiled	_
35-6	6629-6631	to	_
35-7	6632-6636	form	_
35-8	6637-6638	a	_
35-9	6639-6641	68	_
35-10	6642-6643	×	_
35-11	6644-6650	20,647	_
35-12	6651-6659	regional	_
35-13	6660-6673	transcription	_
35-14	6674-6680	matrix	_
35-15	6681-6682	(	_
35-16	6683-6686	see	_
35-17	6687-6697	Supplement	_
35-18	6698-6699	)	_
35-19	6700-6701	.	_

36-1	6702-6705	SRM	_
36-2	6706-6709	and	_
36-3	6710-6715	Human	_
36-4	6716-6721	Brain	_
36-5	6722-6726	Gene	_
36-6	6727-6737	Expression	_
36-7	6738-6740	We	_
36-8	6741-6745	used	_
36-9	6746-6753	partial	_
36-10	6754-6759	least	_
36-11	6760-6767	squares	_
36-12	6768-6769	(	_
36-13	6770-6773	PLS	_
36-14	6774-6775	)	_
36-15	6776-6778	to	_
36-16	6779-6786	analyze	_
36-17	6787-6798	covariation	_
36-18	6799-6806	between	_
36-19	6807-6810	SRM	_
36-20	6811-6814	and	_
36-21	6815-6819	gene	_
36-22	6820-6830	expression	_
36-23	6831-6838	because	_
36-24	6839-6841	it	_
36-25	6842-6844	is	_
36-26	6845-6856	technically	_
36-27	6857-6861	well	_
36-28	6862-6868	suited	_
36-29	6869-6871	to	_
36-30	6872-6875	the	_
36-31	6876-6880	high	_
36-32	6881-6893	collinearity	_
36-33	6894-6896	of	_
36-34	6897-6900	the	_
36-35	6901-6905	gene	_
36-36	6906-6916	expression	_
36-37	6917-6921	data	_
36-38	6922-6923	,	_
36-39	6924-6927	and	_
36-40	6928-6935	because	_
36-41	6936-6939	PLS	_
36-42	6940-6943	and	_
36-43	6944-6947	the	_
36-44	6948-6955	related	_
36-45	6956-6968	multivariate	_
36-46	6969-6975	method	_
36-47	6976-6978	of	_
36-48	6979-6988	canonical	_
36-49	6989-7000	correlation	_
36-50	7001-7009	analysis	_
36-51	7010-7014	have	_
36-52	7015-7019	been	_
36-53	7020-7031	extensively	_
36-54	7032-7041	developed	_
36-55	7042-7045	and	_
36-56	7046-7050	used	_
36-57	7051-7054	for	_
36-58	7055-7067	neuroimaging	_
36-59	7068-7071	and	_
36-60	7072-7087	transcriptional	_
36-61	7088-7092	data	_
36-62	7093-7101	analysis	_
36-63	7102-7103	.	_

37-1	7104-7116	Specifically	_
37-2	7117-7118	,	_
37-3	7119-7121	we	_
37-4	7122-7126	used	_
37-5	7127-7130	PLS	_
37-6	7131-7133	to	_
37-7	7134-7141	analyze	_
37-8	7142-7145	the	_
37-9	7146-7158	relationship	_
37-10	7159-7166	between	_
37-11	7167-7170	the	_
37-12	7171-7177	vector	_
37-13	7178-7180	of	_
37-14	7181-7183	68	_
37-15	7184-7192	regional	_
37-16	7193-7201	measures	_
37-17	7202-7204	of	_
37-18	7205-7208	SRM	_
37-19	7209-7212	and	_
37-20	7213-7216	the	_
37-21	7217-7219	68	_
37-22	7220-7221	×	_
37-23	7222-7228	20,647	_
37-24	7229-7235	matrix	_
37-25	7236-7238	of	_
37-26	7239-7241	68	_
37-27	7242-7250	regional	_
37-28	7251-7260	messenger	_
37-29	7261-7264	RNA	_
37-30	7265-7277	measurements	_
37-31	7278-7281	for	_
37-32	7282-7288	20,647	_
37-33	7289-7294	genes	_
37-34	7295-7296	.	_

38-1	7297-7300	The	_
38-2	7301-7306	first	_
38-3	7307-7310	PLS	_
38-4	7311-7320	component	_
38-5	7321-7322	(	_
38-6	7323-7327	PLS1	_
38-7	7328-7329	)	_
38-8	7330-7333	was	_
38-9	7334-7341	defined	_
38-10	7342-7344	as	_
38-11	7345-7348	the	_
38-12	7349-7357	weighted	_
38-13	7358-7361	sum	_
38-14	7362-7364	of	_
38-15	7365-7377	whole-genome	_
38-16	7378-7388	expression	_
38-17	7389-7393	that	_
38-18	7394-7397	was	_
38-19	7398-7402	most	_
38-20	7403-7411	strongly	_
38-21	7412-7422	correlated	_
38-22	7423-7424	,	_
38-23	7425-7427	or	_
38-24	7428-7432	most	_
38-25	7433-7440	closely	_
38-26	7441-7450	colocated	_
38-27	7451-7452	,	_
38-28	7453-7457	with	_
38-29	7458-7461	the	_
38-30	7462-7472	anatomical	_
38-31	7473-7476	map	_
38-32	7477-7479	of	_
38-33	7480-7483	SRM	_
38-34	7484-7485	.	_

39-1	7486-7497	Permutation	_
39-2	7498-7505	testing	_
39-3	7506-7511	based	_
39-4	7512-7514	on	_
39-5	7515-7524	spherical	_
39-6	7525-7534	rotations	_
39-7	7535-7537	or	_
39-8	7538-7539	“	_
39-9	7540-7545	spins	_
39-10	7546-7547	”	_
39-11	7548-7550	of	_
39-12	7551-7554	the	_
39-13	7555-7564	spatially	_
39-14	7565-7575	correlated	_
39-15	7576-7579	SRM	_
39-16	7580-7583	map	_
39-17	7584-7587	was	_
39-18	7588-7592	used	_
39-19	7593-7595	to	_
39-20	7596-7600	test	_
39-21	7601-7604	the	_
39-22	7605-7609	null	_
39-23	7610-7620	hypothesis	_
39-24	7621-7625	that	_
39-25	7626-7630	PLS1	_
39-26	7631-7640	explained	_
39-27	7641-7643	no	_
39-28	7644-7648	more	_
39-29	7649-7659	covariance	_
39-30	7660-7667	between	_
39-31	7668-7671	SRM	_
39-32	7672-7675	and	_
39-33	7676-7688	whole-genome	_
39-34	7689-7699	expression	_
39-35	7700-7704	than	_
39-36	7705-7713	expected	_
39-37	7714-7716	by	_
39-38	7717-7723	chance	_
39-39	7724-7725	.	_

40-1	7726-7739	Bootstrapping	_
40-2	7740-7743	was	_
40-3	7744-7748	used	_
40-4	7749-7751	to	_
40-5	7752-7760	estimate	_
40-6	7761-7764	the	_
40-7	7765-7776	variability	_
40-8	7777-7779	of	_
40-9	7780-7784	each	_
40-10	7785-7789	gene	_
40-11	7790-7791	’	_
40-12	7792-7793	s	_
40-13	7794-7802	positive	_
40-14	7803-7805	or	_
40-15	7806-7814	negative	_
40-16	7815-7821	weight	_
40-17	7822-7824	on	_
40-18	7825-7829	PLS1	_
40-19	7830-7831	,	_
40-20	7832-7835	and	_
40-21	7836-7838	we	_
40-22	7839-7845	tested	_
40-23	7846-7849	the	_
40-24	7850-7854	null	_
40-25	7855-7865	hypothesis	_
40-26	7866-7868	of	_
40-27	7869-7873	zero	_
40-28	7874-7880	weight	_
40-29	7881-7884	for	_
40-30	7885-7889	each	_
40-31	7890-7894	gene	_
40-32	7895-7899	with	_
40-33	7900-7901	a	_
40-34	7902-7907	false	_
40-35	7908-7917	discovery	_
40-36	7918-7922	rate	_
40-37	7923-7924	(	_
40-38	7925-7928	FDR	_
40-39	7929-7930	)	_
40-40	7931-7933	of	_
40-41	7934-7935	5	_
40-42	7936-7937	%	_
40-43	7938-7939	.	_

41-1	7940-7943	The	_
41-2	7944-7947	set	_
41-3	7948-7950	of	_
41-4	7951-7956	genes	_
41-5	7957-7961	that	_
41-6	7962-7966	were	_
41-7	7967-7980	significantly	_
41-8	7981-7982	(	_
41-9	7983-7993	positively	_
41-10	7994-7996	or	_
41-11	7997-8007	negatively	_
41-12	8008-8009	)	_
41-13	8010-8018	weighted	_
41-14	8019-8021	on	_
41-15	8022-8026	PLS1	_
41-16	8027-8030	was	_
41-17	8031-8037	called	_
41-18	8038-8041	the	_
41-19	8042-8045	SRM	_
41-20	8046-8050	gene	_
41-21	8051-8055	list	_
41-22	8056-8058	or	_
41-23	8059-8062	set	_
41-24	8063-8064	.	_

42-1	8065-8075	Enrichment	_
42-2	8076-8084	Analysis	_
42-3	8085-8087	We	_
42-4	8088-8096	assigned	_
42-5	8097-8098	a	_
42-6	8099-8107	cellular	_
42-7	8108-8119	affiliation	_
42-8	8120-8125	score	_
42-9	8126-8128	to	_
42-10	8129-8133	each	_
42-11	8134-8138	gene	_
42-12	8139-8141	in	_
42-13	8142-8145	the	_
42-14	8146-8149	SRM	_
42-15	8150-8154	gene	_
42-16	8155-8159	list	_
42-17	8160-8169	according	_
42-18	8170-8172	to	_
42-19	8173-8178	prior	_
42-20	8179-8187	criteria	_
42-21	8188-8191	for	_
42-22	8192-8193	4	_
42-23	8194-8198	cell	_
42-24	8199-8211	types—neuron	_
42-25	8212-8213	,	_
42-26	8214-8223	astrocyte	_
42-27	8224-8225	,	_
42-28	8226-8235	microglia	_
42-29	8236-8237	,	_
42-30	8238-8240	or	_
42-31	8241-8256	oligodendroglia	_
42-32	8257-8261	—and	_
42-33	8262-8265	for	_
42-34	8266-8267	a	_
42-35	8268-8272	more	_
42-36	8273-8285	fine-grained	_
42-37	8286-8289	set	_
42-38	8290-8292	of	_
42-39	8293-8297	cell	_
42-40	8298-8303	types	_
42-41	8304-8305	(	_
42-42	8306-8311	Table	_
42-43	8312-8314	S2	_
42-44	8315-8316	)	_
42-45	8317-8318	.	_

43-1	8319-8321	We	_
43-2	8322-8326	used	_
43-3	8327-8328	a	_
43-4	8329-8333	data	_
43-5	8334-8344	resampling	_
43-6	8345-8354	procedure	_
43-7	8355-8357	to	_
43-8	8358-8362	test	_
43-9	8363-8366	the	_
43-10	8367-8371	null	_
43-11	8372-8382	hypothesis	_
43-12	8383-8387	that	_
43-13	8388-8391	SRM	_
43-14	8392-8397	genes	_
43-15	8398-8402	were	_
43-16	8403-8411	randomly	_
43-17	8412-8420	assigned	_
43-18	8421-8423	to	_
43-19	8424-8433	different	_
43-20	8434-8438	cell	_
43-21	8439-8444	types	_
43-22	8445-8446	.	_

44-1	8447-8449	We	_
44-2	8450-8454	used	_
44-3	8455-8456	2	_
44-4	8457-8462	lists	_
44-5	8463-8465	of	_
44-6	8466-8471	genes	_
44-7	8472-8476	that	_
44-8	8477-8481	were	_
44-9	8482-8496	differentially	_
44-10	8497-8506	expressed	_
44-11	8507-8508	,	_
44-12	8509-8511	or	_
44-13	8512-8529	transcriptionally	_
44-14	8530-8542	dysregulated	_
44-15	8543-8544	,	_
44-16	8545-8547	in	_
44-17	8548-8558	postmortem	_
44-18	8559-8564	brain	_
44-19	8565-8571	tissue	_
44-20	8572-8584	measurements	_
44-21	8585-8587	of	_
44-22	8588-8597	messenger	_
44-23	8598-8601	RNA	_
44-24	8602-8606	from	_
44-25	8607-8619	case-control	_
44-26	8620-8627	studies	_
44-27	8628-8630	of	_
44-28	8631-8644	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
44-29	8645-8646	:	_
44-30	8647-8648	1	_
44-31	8649-8650	)	_
44-32	8651-8654	the	_
44-33	8655-8659	list	_
44-34	8660-8662	of	_
44-35	8663-8668	genes	_
44-36	8669-8677	reported	_
44-37	8678-8680	by	_
44-38	8681-8687	Gandal	_
44-39	8688-8690	et	_
44-40	8691-8693	al	_
44-41	8694-8695	.	_

45-1	8696-8698	as	_
45-2	8699-8710	upregulated	_
45-3	8711-8712	(	_
45-4	8713-8714	n	_
45-5	8715-8716	=	_
45-6	8717-8720	845	_
45-7	8721-8722	)	_
45-8	8723-8725	or	_
45-9	8726-8739	downregulated	_
45-10	8740-8741	(	_
45-11	8742-8743	n	_
45-12	8744-8745	=	_
45-13	8746-8750	1175	_
45-14	8751-8752	)	_
45-15	8753-8755	in	_
45-16	8756-8759	the	_
45-17	8760-8770	prefrontal	_
45-18	8771-8774	and	_
45-19	8775-8783	parietal	_
45-20	8784-8789	brain	_
45-21	8790-8797	regions	_
45-22	8798-8800	in	_
45-23	8801-8814	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
45-24	8815-8816	(	_
45-25	8817-8818	n	_
45-26	8819-8820	=	_
45-27	8821-8824	159	_
45-28	8825-8826	)	_
45-29	8827-8828	;	_
45-30	8829-8832	and	_
45-31	8833-8834	2	_
45-32	8835-8836	)	_
45-33	8837-8840	the	_
45-34	8841-8845	list	_
45-35	8846-8848	of	_
45-36	8849-8854	genes	_
45-37	8855-8863	reported	_
45-38	8864-8866	by	_
45-39	8867-8873	Fromer	_
45-40	8874-8876	et	_
45-41	8877-8879	al	_
45-42	8880-8881	.	_

46-1	8882-8884	as	_
46-2	8885-8896	upregulated	_
46-3	8897-8898	(	_
46-4	8899-8900	n	_
46-5	8901-8902	=	_
46-6	8903-8906	304	_
46-7	8907-8908	)	_
46-8	8909-8911	or	_
46-9	8912-8925	downregulated	_
46-10	8926-8927	(	_
46-11	8928-8929	n	_
46-12	8930-8931	=	_
46-13	8932-8935	345	_
46-14	8936-8937	)	_
46-15	8938-8940	in	_
46-16	8941-8944	the	_
46-17	8945-8957	dorsolateral	_
46-18	8958-8968	prefrontal	_
46-19	8969-8975	cortex	_
46-20	8976-8978	in	_
46-21	8979-8992	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
46-22	8993-8994	(	_
46-23	8995-8996	n	_
46-24	8997-8998	=	_
46-25	8999-9002	258	_
46-26	9003-9004	)	_
46-27	9005-9006	.	_

47-1	9007-9010	The	_
47-2	9011-9012	2	_
47-3	9013-9017	gene	_
47-4	9018-9023	lists	_
47-5	9024-9028	were	_
47-6	9029-9038	partially	_
47-7	9039-9050	overlapping	_
47-8	9051-9052	(	_
47-9	9053-9058	Table	_
47-10	9059-9061	S3	_
47-11	9062-9063	)	_
47-12	9064-9065	,	_
47-13	9066-9069	and	_
47-14	9070-9082	differential	_
47-15	9083-9093	expression	_
47-16	9094-9096	of	_
47-17	9097-9100	all	_
47-18	9101-9106	genes	_
47-19	9107-9115	subsumed	_
47-20	9116-9118	by	_
47-21	9119-9122	the	_
47-22	9123-9128	union	_
47-23	9129-9131	of	_
47-24	9132-9135	the	_
47-25	9136-9137	2	_
47-26	9138-9143	lists	_
47-27	9144-9147	was	_
47-28	9148-9156	strongly	_
47-29	9157-9167	correlated	_
47-30	9168-9175	between	_
47-31	9176-9183	studies	_
47-32	9184-9185	(	_
47-33	9186-9187	ρ	_
47-34	9188-9189	=	_
47-35	9190-9193	.76	_
47-36	9194-9195	,	_
47-37	9196-9197	p	_
47-38	9198-9199	<	_
47-39	9200-9206	10−129	_
47-40	9207-9208	)	_
47-41	9209-9210	(	_
47-42	9211-9217	Figure	_
47-43	9218-9220	S1	_
47-44	9221-9222	)	_
47-45	9223-9224	.	_

48-1	9225-9227	We	_
48-2	9228-9232	used	_
48-3	9233-9241	repeated	_
48-4	9242-9248	random	_
48-5	9249-9259	relabeling	_
48-6	9260-9262	of	_
48-7	9263-9268	genes	_
48-8	9269-9271	to	_
48-9	9272-9276	test	_
48-10	9277-9280	the	_
48-11	9281-9285	null	_
48-12	9286-9296	hypothesis	_
48-13	9297-9301	that	_
48-14	9302-9305	the	_
48-15	9306-9309	SRM	_
48-16	9310-9314	gene	_
48-17	9315-9319	list	_
48-18	9320-9328	included	_
48-19	9329-9331	no	_
48-20	9332-9336	more	_
48-21	9337-9358	schizophrenia-related	_
48-22	9359-9364	genes	_
48-23	9365-9369	than	_
48-24	9370-9378	expected	_
48-25	9379-9381	by	_
48-26	9382-9388	chance	_
48-27	9389-9390	.	_

49-1	9391-9393	We	_
49-2	9394-9398	also	_
49-3	9399-9406	applied	_
49-4	9407-9410	the	_
49-5	9411-9415	same	_
49-6	9416-9426	resampling	_
49-7	9427-9437	procedures	_
49-8	9438-9440	to	_
49-9	9441-9451	comparable	_
49-10	9452-9457	prior	_
49-11	9458-9462	data	_
49-12	9463-9465	on	_
49-13	9466-9478	differential	_
49-14	9479-9483	gene	_
49-15	9484-9494	expression	_
49-16	9495-9499	from	_
49-17	9500-9512	case-control	_
49-18	9513-9520	studies	_
49-19	9521-9523	of	_
49-20	9524-9536	inflammatory	_
49-21	9537-9542	bowel	_
49-22	9543-9550	disease	_
49-23	9551-9552	,	_
49-24	9553-9560	bipolar	_
49-25	9561-9569	disorder	_
49-26	9570-9571	(	_
49-27	9572-9575	BPD	_
49-28	9576-9577	)	_
49-29	9578-9579	,	_
49-30	9580-9585	major	_
49-31	9586-9596	depressive	_
49-32	9597-9605	disorder	_
49-33	9606-9607	,	_
49-34	9608-9611	and	_
49-35	9612-9618	autism	_
49-36	9619-9627	spectrum	_
49-37	9628-9636	disorder	_
49-38	9637-9638	(	_
49-39	9639-9642	ASD	_
49-40	9643-9644	)	_
49-41	9645-9646	.	_

50-1	9647-9651	Data	_
50-2	9652-9655	and	_
50-3	9656-9660	Code	_
50-4	9661-9668	Sharing	_
50-5	9669-9673	Data	_
50-6	9674-9682	Regional	_
50-7	9683-9685	MT	_
50-8	9686-9689	for	_
50-9	9690-9692	68	_
50-10	9693-9701	cortical	_
50-11	9702-9709	regions	_
50-12	9710-9711	,	_
50-13	9712-9722	schizotypy	_
50-14	9723-9729	scores	_
50-15	9730-9731	,	_
50-16	9732-9735	age	_
50-17	9736-9737	,	_
50-18	9738-9744	gender	_
50-19	9745-9746	,	_
50-20	9747-9760	socioeconomic	_
50-21	9761-9767	status	_
50-22	9768-9769	,	_
50-23	9770-9778	scanning	_
50-24	9779-9783	site	_
50-25	9784-9785	,	_
50-26	9786-9791	total	_
50-27	9792-9797	brain	_
50-28	9798-9804	volume	_
50-29	9805-9806	,	_
50-30	9807-9810	and	_
50-31	9811-9816	Euler	_
50-32	9817-9823	values	_
50-33	9824-9825	(	_
50-34	9826-9829	for	_
50-35	9830-9831	N	_
50-36	9832-9833	=	_
50-37	9834-9837	248	_
50-38	9838-9839	)	_
50-39	9840-9843	are	_
50-40	9844-9853	available	_
50-41	9854-9856	at	_
50-42	9857-9862	https	_
50-43	9863-9864	:	_
50-44	9865-9918	//github.com/RafaelRomeroGarcia/Schizotypy_MT_geneExp	_
50-45	9919-9920	.	_

51-1	9921-9925	Code	_
51-2	9926-9934	Cortical	_
51-3	9935-9947	parcellation	_
51-4	9948-9950	of	_
51-5	9951-9955	gene	_
51-6	9956-9966	expression	_
51-7	9967-9971	maps	_
51-8	9972-9974	to	_
51-9	9975-9983	estimate	_
51-10	9984-9992	regional	_
51-11	9993-9997	mean	_
51-12	9998-10002	gene	_
51-13	10003-10013	expression	_
51-14	10014-10017	can	_
51-15	10018-10020	be	_
51-16	10021-10026	found	_
51-17	10027-10029	at	_
51-18	10030-10035	https	_
51-19	10036-10037	:	_
51-20	10038-10095	//github.com/RafaelRomeroGarcia/geneExpression_Repository	_
51-21	10096-10097	.	_

52-1	10098-10101	The	_
52-2	10102-10121	rotate_parcellation	_
52-3	10122-10126	code	_
52-4	10127-10136	generates	_
52-5	10137-10141	null	_
52-6	10142-10148	models	_
52-7	10149-10153	that	_
52-8	10154-10162	preserve	_
52-9	10163-10166	the	_
52-10	10167-10174	spatial	_
52-11	10175-10185	contiguity	_
52-12	10186-10188	of	_
52-13	10189-10197	cortical	_
52-14	10198-10205	regions	_
52-15	10206-10209	for	_
52-16	10210-10221	permutation	_
52-17	10222-10229	testing	_
52-18	10230-10231	:	_
52-19	10232-10237	https	_
52-20	10238-10239	:	_
52-21	10240-10286	//github.com/frantisekvasa/rotate_parcellation	_
52-22	10287-10288	.	_

53-1	10289-10292	PLS	_
53-2	10293-10301	analysis	_
53-3	10302-10305	and	_
53-4	10306-10319	bootstrapping	_
53-5	10320-10322	to	_
53-6	10323-10331	estimate	_
53-7	10332-10335	PLS	_
53-8	10336-10343	weights	_
53-9	10344-10347	can	_
53-10	10348-10350	be	_
53-11	10351-10356	found	_
53-12	10357-10359	at	_
53-13	10360-10365	https	_
53-14	10366-10367	:	_
53-15	10368-10441	//github.com/KirstieJane/NSPN_WhitakerVertes_PNAS2016/tree/master/SCRIPTS	_
53-16	10442-10443	.	_

54-1	10444-10446	To	_
54-2	10447-10455	generate	_
54-3	10456-10462	Figure	_
54-4	10463-10465	S1	_
54-5	10466-10470	from	_
54-6	10471-10474	the	_
54-7	10475-10478	raw	_
54-8	10479-10485	Gandal	_
54-9	10486-10488	et	_
54-10	10489-10491	al	_
54-11	10492-10493	.	_

55-1	10494-10497	and	_
55-2	10498-10504	Fromer	_
55-3	10505-10507	et	_
55-4	10508-10510	al	_
55-5	10511-10512	.	_

56-1	10513-10521	datasets	_
56-2	10522-10523	,	_
56-3	10524-10526	we	_
56-4	10527-10531	used	_
56-5	10532-10537	https	_
56-6	10538-10539	:	_
56-7	10540-10593	//github.com/RafaelRomeroGarcia/Schizotypy_MT_geneExp	_
56-8	10594-10595	.	_

57-1	10596-10599	For	_
57-2	10600-10607	mapping	_
57-3	10608-10616	regional	_
57-4	10617-10623	values	_
57-5	10624-10626	to	_
57-6	10627-10630	the	_
57-7	10631-10639	cortical	_
57-8	10640-10647	surface	_
57-9	10648-10651	for	_
57-10	10652-10665	visualization	_
57-11	10666-10667	(	_
57-12	10668-10688	BrainsForPublication	_
57-13	10689-10695	v0.2.1	_
57-14	10696-10697	)	_
57-15	10698-10699	,	_
57-16	10700-10703	see	_
57-17	10704-10709	https	_
57-18	10710-10711	:	_
57-19	10712-10744	//doi.org/10.5281/zenodo.1069156	_
57-20	10745-10746	.	_

